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TO THE EDITOR
Systemic administration of nitrite (NO2
)
affords protection against ischemia/
reperfusion-related organ damage
(Lundberg et al., 2008), whereas topical
nitrite application exerts local antimi-
crobial effects and promotes wound
healing (Weller et al., 2001; Weller
and Finnen, 2006). The latter two
actions require acidification, are often
accompanied by increased blood flow
(Tucker et al., 1999; Gribbe et al.,
2008), and are thought to be mediated
by the formation of nitric oxide (NO),
albeit not all effects of nitrite necessa-
rily occur through NO generation
(Bryan et al., 2005). Although the
significance of NO in cutaneous phy-
siology is widely recognized (Bruch-
Gerharz et al., 1998; Weller, 2003), the
relevance and biological function of its
oxidation product, nitrite, are incom-
pletely understood (Suschek et al.,
2006), as is the mechanism by which
dermal nitrite couples to systemic NO/
nitrite physiology.
Nitrite concentrations in human skin
are considerably higher than those in
circulation (Paunel et al., 2005; Mow-
bray et al., 2009) and are a reflection of
local NO synthase activity. Nitrite is
also a constituent of human sweat,
possibly produced via reduction of
nitrate by commensal heterotrophic
bacteria colonizing the skin (Weller
et al., 1996). The actions of nitrite in
or on the skin have been proposed to
contribute to host defense against skin
pathogens and include modulation of
cutaneous T-cell function, keratinocyte
differentiation, blood flow, and protec-
tion against UV-radiation damage
(Weller et al., 1996; Suschek et al.,
2006). Whether these actions of nitrite
extend beyond the skin is unknown.
Recently, nitrite production via auto-
trophic oxidation of ammonia by der-
mal microflora has been proposed to
contribute to bodily NO status and
immune system function (Whitlock
and Feelisch, 2009). An important
prerequisite for the validity of this
concept is nitrite’s ability to permeate
the skin. Although substances with a
molecular weight of o500 Da are be-
lieved to cross the stratum corneum with
ease (Bos and Meinardi, 2000), the same
rules may not apply for negatively char-
ged ions (nitrous acid (HNO2) has a pKa
of 3.4 and is thus largely (499.9%)
dissociated at physiological pH; Butler
and Ridd, 2004). Apart from anecdotal
evidence of fatal methemoglobinemia
after application of a liniment containing
large quantities of nitrite (Saito et al.,
1996, 1997), no information on dermal
nitrite uptake is available. We therefore
sought to investigate, using a rodent
model, whether nitrite permeates the
skin to reach internal organs through
the circulation.
Pharmacologically relevant doses of
nitrite (0.1, 1.0, and 10 mg kg1 in
phosphate-buffered saline; pH 7.4) or
vehicle were topically applied in equal
volumes (800 ml) to a shaved area of
dorsal skin, and concentrations of
several NO-related metabolites (nitrite,
nitrate, S- and N-nitroso compounds
(RXNO), and NO-heme species) were
determined simultaneously in multiple
compartments using extensively validated
ion-chromatographic and gas-phase
chemiluminescence-based techniques
(Feelisch et al., 2002; Rodriguez et al.,
2003; Bryan et al., 2004) (see Supple-
mentary Materials for details). We find
(i) that no acidification is required to
increase NO-related metabolites in
blood and tissues and (ii) that compart-
ments in which increases occur include
those important for priming and func-
tional modulation of immune cellsAbbreviations: NO, nitric oxide; RXNO, S- and N-nitroso compounds
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(thymus, spleen, and peripheral lymph
nodes). Because all the NO-related
metabolites determined either can be
metabolized to NO or are endowed
with NO-like bioactivities, dermal ni-
trite application would seem to lead to
global increases in NO availability,
with consequent modulation of organ
and immune cell function. In support of
this notion, nitrite was found to potently
inhibit T-cell and other inflammatory
cell accumulation in the lung and
airway secretion of IL-13 in a murine
model of allergic asthma.
Although nitrite penetration through
skin per se is perhaps not surprising, the
speed and efficacy with which this
process occurred were unexpected.
Dose-proportional increases in NO-
related metabolites were monitored in
three representative compartments
(plasma, heart, and liver) and became
evident within minutes of nitrite appli-
cation, with concentrations peaking
within 5–15 minutes, depending on the
compartment under study (Figure 1,
inset(s)). Maximal concentrations of
NO-related metabolites were three- to
sixfold lower after dermal application,
compared with intraperitoneal admin-
istration of equivalent doses (Bryan
et al., 2005), but no effort was
undertaken to directly compare rates
and the extent of uptake between
application routes. Topical adminis-
tration of nitrite-free vehicle did not
significantly change basal levels (data
not shown). Figure 1 depicts the effects
of 10 mg kg1 nitrite at 15 minutes
after application. Marked increases in
nitrite, nitrate, RXNO, and NO-heme
species were observed in most, but
not all, compartments. Notable exce-
ptions were kidney (nitrite), brain
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Figure 1. (a–d) Concentration of nitric oxide (NO)-related metabolites in blood and tissues 15minutes after dermal application of pH-neutral solutions
of sodium nitrite (10mg kg1; n¼3) or vehicle (n¼5). The NO-related metabolites measured include nitrite, nitrate, S- and N-nitroso compounds (RXNO),
and nitrosyl (NO-heme) species. Excluding the brain, which showed no change (RXNO, NO-heme) or decreased (nitrate) concentrations along with the
kidney (nitrite), appreciable increases in NO-related metabolites were observed in other compartments. Significant nitrite oxidation seems to occur only
in the blood, heart, and kidney. Insets: time courses of uptake and metabolism of dermal nitrite for three representative compartments (plasma, heart, liver).
Within minutes, marked increases in NO-related metabolites (nitrite, nitrate, RXNO, NO-heme) were evident (RBC, red blood cell; bql, below quantifiable
limit; *Po0.05, **Po0.01 versus vehicle).
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(nitrate, RXNO, NO-heme), and plasma
(RXNO, NO-heme), in which either
no change or a decrease in select
NO-related metabolites occurred. Robust
increases in circulating nitrite, in con-
junction with a lack of enhancement of
plasma nitrosation products, suggest
that S-nitrosoalbumin has only a minor
role in transferring NO equivalents
from skin to other organs, at least under
these conditions. Therefore, the major-
ity of metabolic conversion into other
NO-related species probably occurs
within blood cells and tissues.
Although there is precedence for
increased NO-related metabolites in
blood and tissues after systemic nitrite
administration (Bryan et al., 2005),
information regarding its effects on the
immune system is scarce (Ustyugova
et al., 2002; Cape and Hurst, 2009).
Lymph nodes from vehicle-treated ani-
mals showed remarkably high nitrite/
nitrate concentrations, indicative of
high NO production rates under basal
conditions (Table 1). Dermal nitrite
application (10 mg kg1) induced wide-
spread changes in NO-related meta-
bolites within thymus, spleen, and
peripheral lymph nodes, depicting
clear increases for most—except RXNO,
which decreased in thymus and lymph
nodes. Preliminary analysis of the
CD3-positive cell fraction of lymph
nodes confirmed that, whereas intracel-
lular nitrite and nitrate concentrations
double, S-nitrosation of T cells drops by
45–60% shortly after dermal nitrite
application. Little is known about the
effects of changes in protein nitrosation
on immune cell activity, but various
functional consequences are likely,
given the importance of redox-based
signaling (Janssen-Heininger et al.,
2008) and the versatility of NO in
regulating T-cell, dendritic cell, and
macrophage function in particular and
immune responses in general (Bogdan,
2001; Niedbala et al., 2006; Mowbray
et al., 2008).
Cells oxidize NO to nitrite, and
nitrite can be reduced back to NO
under certain conditions, yet the biol-
ogy of these two species is not inter-
changeable and actions of nitrite
cannot be simply inferred from known
effects of NO. We therefore sought to
obtain direct evidence for immunomo-
dulation by nitrite in T-cell receptor
transgenic mice challenged with aero-
solized ovalbumin. Using this model of
allergic asthma (Wilder et al., 2001),
we found that nitrite (10 mg l1 admi-
nistered for 4 days with drinking water)
potently inhibits the number of T
lymphocytes and other inflammatory
cells, as well as the production of the
Th2-derived effector cytokine, IL-13, in
bronchial alveolar lavage fluid (Supple-
mentary Figure 1).
Collectively, our findings suggest
that dermal nitrite administration pro-
vides a simple, noninvasive alternative
to other application forms that can be
conveniently used for percutaneous
systemic therapy (presumably with low-
er risk of N-nitrosamine formation
compared with oral application). Our
results may also have important phy-
siological implications inasmuch
as sweat-derived nitrite, from nitrate
reduction or ammonia oxidation, seems
to have the potential to affect immune
responses through modulation of
NO availability. Collectively, these
observations may shift the current
emphasis of nitrite from cardiovascular
pharmacology to immunology. Further
investigations are warranted to confirm
our findings and explore their thera-
peutic potential.
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Table 1. NO-related metabolites in immune-relevant compartments
15minutes after dermal application of 10mg kg1 sodium nitrite (in PBS,
pH 7.4) compared with effects of vehicle (PBS) alone
Vehicle (n=5) Nitrite (n=3)
Thymus
Nitrite 0.07±0.04 3.36±1.33*
Nitrate 2.96±0.64 5.13±1.56
RXNO 0.24±0.06 0.20±0.02
NO-heme 4.34±2.97 11.6±1.9
Spleen
Nitrite o0.04 1.44±0.57*
Nitrate 1.17±0.15 5.92±1.00**
RXNO 0.09±0.01 0.99±0.46*
NO-heme 1.24±0.85 12.2±5.86*
Lymph nodes
Nitrite 3.71±1.29 8.53±1.91
Nitrate 40.78±25.21 84.25±42.29
RXNO 0.08±0.05 0.04±0.02
NO-heme ND ND
NO, nitric oxide; PBS, phosphate-buffered saline; RXNO, S- and N-nitroso compounds.
The compartment denoted as ‘‘lymph nodes’’ is a homogenate of pooled superficial cervical,
anxillary, and iliac lymph nodes (ND, not determined owing to limited sample availability). Data are
means±SEM from n individual experiments and expressed as nmoles per gram wet weight (for nitrite,
nitrate, and RXNO) and pmoles per gram wet weight for NO-heme products; *Po0.05, **Po0.01
versus vehicle.
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The Extent of Orthorhombic Lipid Phases in the Stratum
Corneum Determines the Barrier Efficiency of Human Skin
In Vivo
Journal of Investigative Dermatology (2010) 130, 611–614; doi:10.1038/jid.2009.272; published online 3 September 2009
TO THE EDITOR
The outermost skin layer—the stratum
corneum (SC)—constitutes the main
barrier for the fluxes of water and
chemicals through human skin (Elias,
2004). Here, we report on the molecular
organization of the SC extracellular
lipid matrix and its role in skin barrier
efficiency. Using attenuated total internal
reflection Fourier-transform infrared
spectroscopy and measurements of trans-
epidermal water loss (TEWL) on intact
Abbreviations: FWHM, full width at 50% peak height; HEX, hexagonal; LIQ, liquid-crystalline; OR,
orthorhombic; SC, stratum corneum; TEWL, transepidermal water loss
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